EP1515956A4 - Peptiddeformylaseinhibitoren - Google Patents

Peptiddeformylaseinhibitoren

Info

Publication number
EP1515956A4
EP1515956A4 EP03739066A EP03739066A EP1515956A4 EP 1515956 A4 EP1515956 A4 EP 1515956A4 EP 03739066 A EP03739066 A EP 03739066A EP 03739066 A EP03739066 A EP 03739066A EP 1515956 A4 EP1515956 A4 EP 1515956A4
Authority
EP
European Patent Office
Prior art keywords
peptide deformylase
deformylase inhibitors
inhibitors
peptide
deformylase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03739066A
Other languages
English (en)
French (fr)
Other versions
EP1515956A1 (de
Inventor
Joseph M Karpinski
Kelly M Aubart
Siegfried B Christensen Iv
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP1515956A1 publication Critical patent/EP1515956A1/de
Publication of EP1515956A4 publication Critical patent/EP1515956A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP03739066A 2002-06-06 2003-06-06 Peptiddeformylaseinhibitoren Withdrawn EP1515956A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38669702P 2002-06-06 2002-06-06
US386697P 2002-06-06
PCT/US2003/018075 WO2003104209A1 (en) 2002-06-06 2003-06-06 Peptide deformylase inhibitors

Publications (2)

Publication Number Publication Date
EP1515956A1 EP1515956A1 (de) 2005-03-23
EP1515956A4 true EP1515956A4 (de) 2005-08-10

Family

ID=29736198

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03739066A Withdrawn EP1515956A4 (de) 2002-06-06 2003-06-06 Peptiddeformylaseinhibitoren

Country Status (4)

Country Link
EP (1) EP1515956A4 (de)
JP (1) JP2005532358A (de)
AU (1) AU2003245423A1 (de)
WO (1) WO2003104209A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100862645B1 (ko) 2007-05-18 2008-10-09 한국생명공학연구원 펩타이드 디포밀레이즈 저해 및 항균활성을 갖는 신규후미마이신 화합물
EP2959898A1 (de) 2009-05-05 2015-12-30 Sloan-Kettering Institute for Cancer Research 4,5-DIOXO-NAPHTHO[1,2-b]FURAN-VERBINDUNGEN ALS SELEKTIVE PEPTIDDEFORMYLASEHEMMER

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044188A1 (en) * 1999-12-17 2001-06-21 Darwin Discovery Limited Hydroxamic acid derivatives as matrix metalloproteinase (mmp) inhibitors
WO2002070541A2 (en) * 2001-03-01 2002-09-12 Smith Kline Beecham Corporation Peptide deformylase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002322035A1 (en) * 2001-06-05 2002-12-16 Smithkline Beecham Corporation Peptide deformylase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044188A1 (en) * 1999-12-17 2001-06-21 Darwin Discovery Limited Hydroxamic acid derivatives as matrix metalloproteinase (mmp) inhibitors
WO2002070541A2 (en) * 2001-03-01 2002-09-12 Smith Kline Beecham Corporation Peptide deformylase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO03104209A1 *

Also Published As

Publication number Publication date
EP1515956A1 (de) 2005-03-23
AU2003245423A1 (en) 2003-12-22
JP2005532358A (ja) 2005-10-27
WO2003104209A1 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
EG25482A (en) Inhibitors
EP1499336A4 (de) Proteasehemmer
IL164973A0 (en) Peptide deformylase inhibitors
EP1532133A4 (de) Nf-:b-inhibitoren
EG24516A (en) Peptide deformylase inhibitors
AU2003296960A8 (en) Peptide deformylase inhibitors
AU2003269984A8 (en) Protease inhibitors
IL163935A0 (en) Plasma carboxypeptidase b inhibitors
IL152638A0 (en) Peptide deformylase inhibitors
EP1383729A4 (de) Peptiddeformylaseinhibitoren
IL151884A0 (en) Peptide deformylase inhibitors
AU2003263738A8 (en) Protease inhibitors
EP1499318A4 (de) Peptiddeformylase-aktivierte prodrugs
EP1515956A4 (de) Peptiddeformylaseinhibitoren
AU2002255634A1 (en) Peptide deformylase inhibitors
AU2003212418A8 (en) Peptide deformylase
AU2003233642A8 (en) Protease inhibitors
AU2003304496A8 (en) Protease inhibitors
AU2003269878A8 (en) Protease inhibitors
AU2003265240A8 (en) Protease inhibitors
AU2003215235A8 (en) Cks1 inhibitors
GB0217330D0 (en) Inhibitors
GB0208094D0 (en) Inhibitors
GB0207491D0 (en) Inhibitors
GB0206031D0 (en) Inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20050628

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 31/04 B

Ipc: 7A 61K 31/343 B

Ipc: 7A 61K 31/4192 B

Ipc: 7A 61K 31/433 B

Ipc: 7A 61K 31/498 B

Ipc: 7C 07D 235/04 B

Ipc: 7C 07D 307/78 B

Ipc: 7C 07D 241/42 B

Ipc: 7C 07D 249/18 A

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20041213

Extension state: LT

Payment date: 20041213

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060627